Investigational drug · Phase 2
AP-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "AP-101"
First trial start
2021
Sep 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AP-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "AP-101" as an intervention, largest first.
AL-S PharmaIndustry
NCT05039099 · 73 participants · Start Sep 2, 2021 · Primary completion Aug 13, 2025
Drug: AP-101; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: La Jolla, California; Leuven, Belgium; Edmonton, Canada · 13 sites in all
- A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast CancerCompleted
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05190770 · 18 participants · Start Dec 15, 2021 · Primary completion Aug 27, 2024
Drug: Triamcinolone Acetonide; Oleogel-S10 · For: Breast Cancer; Breast Cancer Stage; Breast Cancer Stage I and 3 more
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Harrison, New York · 4 sites in all
- A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)Status unknown
AL-S PharmaIndustry
NCT03981536 · 18 participants (planned) · Start Oct 10, 2019 · Primary completion Nov 2, 2020
Drug: AP-101 · For: Amyotrophic Lateral Sclerosis
Sites: London, Canada; Toronto, Canada; Montreal, Canada
Université de SherbrookeAcademic, hospital or other
NCT05974579 · 8 participants · Start Nov 23, 2023 · Primary completion Dec 30, 2024
Drug: 89Zr-DFO-AP-101 · For: Amyotrophic Lateral Sclerosis
Sites: Sherbrooke, Canada
Newest research
PubMed records naming it or its code names, newest first.
- A phase I study to evaluate the dosimetry and safety of [89Zr]Zr-DFO-AP-101, a new antibody-based radiopharmaceutical to detect misfolded SOD1 in amyotrophic lateral sclerosis.
Croteau E, Rousseau E, Tremblay S, et al. · Eur J Nucl Med Mol Imaging 2026
Also in development for Amyotrophic Lateral Sclerosis
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- MN-166ibudilastPhase 31 trial
MediciNova · Amyotrophic Lateral Sclerosis
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- BIIB147Phase 21 trial
Biogen · Amyotrophic Lateral Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.